Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ANGION BIOMEDICA CORP.

(ANGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Angion Biomedica : to Participate in Upcoming September Investment Conferences

09/02/2021 | 12:20am EDT

UNIONDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced its management team will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference and participate in a fireside chat with Oppenheimer Senior Biotech Analyst Justin Kim at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.

Details are as follows:

Event: H.C. Wainwright 23rd Annual Global Investment Conference
Date: Monday, September 13th
Time: 7:00am Eastern US Daylight Time

Event: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: Wednesday, September 22nd
Time: 10:45am Eastern US Daylight Time

Webcasts of the presentation and fireside chat will be accessible online by visiting the events and presentations page under the investors section of Angion’s website at https://ir.angion.com/events-presentations. The webcasts of both events will remain archived on Angion’s website for approximately 30 days.

About Angion
Angion is committed to transforming the treatment paradigm for patients suffering from acute organ injuries and fibrotic diseases for which there are no approved medicines or where existing approved medicines have limitations. Angion’s lead product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic currently being evaluated in a Phase 3 registration trial for delayed graft function in patients undergoing deceased donor kidney transplantation and a Phase 2 trial in cardiac-surgery associated acute kidney injury. Angion is scheduled to begin a Phase 2 trial evaluating ANG-3070, an oral tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in patients with primary proteinuric kidney diseases. Additionally, Angion has preclinical programs for a rho kinase 2 (ROCK2) inhibitor and a CYP11B2 (aldosterone synthase) inhibitor. For more information, please visit www.angion.com.


Contact
Daniel Ferry
LifeSci Advisors
617-430-7576
daniel@lifesciadvisors.com

Primary Logo

Source: Angion Biomedica Corp.

2021 GlobeNewswire, Inc., source Press Releases

All news about ANGION BIOMEDICA CORP.
10/18ANGION BIOMEDICA : to Present Multiple Posters at Kidney Week 2021
AQ
09/08ANGION BIOMEDICA : Hosting Research & Development Day on ANG-3070 for the Treatment of Lun..
AQ
09/02ANGION BIOMEDICA : to Participate in Upcoming September Investment Conferences
AQ
08/30ANGION BIOMEDICA : Termination of Material Definitive Agreement (Form 8-K)
PU
08/30ANGION BIOMEDICA CORP. : Termination of a Material Definitive Agreement (form 8-K)
AQ
08/30Sinovant Sciences HK Limited Intends to Terminate Its Exclusive License Agreement with ..
CI
08/12ANGION BIOMEDICA : Provides Corporate Update and Reports Second Quarter 2021 Financial Res..
PU
08/12ANGION BIOMEDICA : Earnings Flash (ANGN) ANGION BIOMEDICA Reports Q2 Loss $-0.58
MT
08/12ANGION BIOMEDICA : Earnings Flash (ANGN) ANGION BIOMEDICA Reports Q2 Revenue $540,000
MT
08/12ANGION BIOMEDICA CORP. : Results of Operations and Financial Condition, Financial Statemen..
AQ
More news
Analyst Recommendations on ANGION BIOMEDICA CORP.
More recommendations
Financials (USD)
Sales 2021 3,30 M - -
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 255 M 255 M -
Capi. / Sales 2021 77,5x
Capi. / Sales 2022 19,4x
Nbr of Employees 72
Free-Float 59,4%
Chart ANGION BIOMEDICA CORP.
Duration : Period :
Angion Biomedica Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 8,57 $
Average target price 59,33 $
Spread / Average Target 592%
Managers and Directors
Jay R. Venkatesan President, Chief Executive Officer & Director
Greg S. Curhan Chief Financial Officer
Itzhak D. Goldberg Executive Chairman & Chief Scientific Officer
John F. Neylan Chief Medical Officer & Senior Vice President
Jennifer J. Rhodes Secretary, Chief Compliance Office & Senior VP
Sector and Competitors
1st jan.Capi. (M$)
ANGION BIOMEDICA CORP.0.00%255
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 092
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455